| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/17476348.2015.995640 |
| P698 | PubMed publication ID | 25541089 |
| P50 | author | María D Maciá | Q79793431 |
| Carla López-Causapé | Q85964688 | ||
| P2093 | author name string | Antonio Oliver | |
| Estrella Rojo-Molinero | |||
| P2860 | cites work | Extracellular DNA Required for Bacterial Biofilm Formation | Q22065541 |
| A component of innate immunity prevents bacterial biofilm development | Q24298499 | ||
| Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients | Q24551181 | ||
| A fatty acid messenger is responsible for inducing dispersion in microbial biofilms | Q24647900 | ||
| Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa | Q24673124 | ||
| The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity | Q24683150 | ||
| Nitric oxide production by polymorphonuclear leucocytes in infected cystic fibrosis sputum consumes oxygen | Q46921876 | ||
| Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms | Q46977483 | ||
| Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis | Q47599080 | ||
| Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa | Q47741962 | ||
| Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial | Q47751601 | ||
| Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. | Q50452988 | ||
| Metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from a cystic fibrosis patient. | Q51715013 | ||
| Proteins with GGDEF and EAL domains regulate Pseudomonas putida biofilm formation and dispersal. | Q54453322 | ||
| Cystic fibrosis | Q55881299 | ||
| Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota | Q56220182 | ||
| High β-lactamase levels change the pharmacodynamics of β-lactam antibiotics in Pseudomonas aeruginosa biofilms | Q42529536 | ||
| Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. | Q42563377 | ||
| Emergence of an epidemic clone of community-associated methicillin-resistant panton-valentine leucocidin-negative Staphylococcus aureus in cystic fibrosis patient populations. | Q42637580 | ||
| Bap, a Staphylococcus aureus surface protein involved in biofilm formation | Q42737702 | ||
| Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections. | Q42909082 | ||
| Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. | Q43077048 | ||
| Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants | Q43153453 | ||
| Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa | Q43189616 | ||
| Gene expression in Pseudomonas aeruginosa biofilms | Q43777487 | ||
| An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre | Q44021808 | ||
| High Rate of Macrolide Resistance inStaphylococcus aureusStrains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains | Q44195004 | ||
| Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection. | Q44367885 | ||
| Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa | Q44588508 | ||
| Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa | Q44877341 | ||
| Complex molecular epidemiology of methicillin-resistant staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus | Q45411110 | ||
| High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation | Q46468467 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| Increased mutability of Pseudomonas aeruginosa in biofilms | Q46767850 | ||
| Multiple roles of biosurfactants in structural biofilm development by Pseudomonas aeruginosa | Q24683834 | ||
| Characterization of Pseudomonas aeruginosa isolated from chronically infected children with cystic fibrosis in India | Q24810743 | ||
| Antibiotic resistance of bacteria in biofilms | Q28207706 | ||
| Pseudomonas aeruginosa: all roads lead to resistance | Q28240246 | ||
| Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa | Q28492507 | ||
| Biofilm formation as microbial development | Q29619202 | ||
| Persister cells | Q30018300 | ||
| Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. | Q31029779 | ||
| The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection | Q33386642 | ||
| The changing microbial epidemiology in cystic fibrosis | Q33825634 | ||
| Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention | Q33828309 | ||
| Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. | Q33859051 | ||
| Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis | Q33874056 | ||
| Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis | Q33982025 | ||
| Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. | Q34140808 | ||
| Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa | Q34143161 | ||
| Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection | Q34233774 | ||
| High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. | Q34508854 | ||
| Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa | Q34509793 | ||
| Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin | Q34720396 | ||
| Mutation and evolution of antibiotic resistance: antibiotics as promoters of antibiotic resistance? | Q34725726 | ||
| Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes | Q34757004 | ||
| Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. | Q34948367 | ||
| Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy | Q35140423 | ||
| Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia | Q35532451 | ||
| Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis | Q35563227 | ||
| Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. | Q35879111 | ||
| VEB-1 in Achromobacter xylosoxidans from cystic fibrosis patient, France | Q36023539 | ||
| Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro | Q36095041 | ||
| Targeted Antibiotic Prophylaxis for Lung Transplantation in Cystic Fibrosis Patients Colonised with Pseudomonas aeruginosa Using Multiple Combination Bactericidal Testing | Q36118861 | ||
| Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation | Q36295397 | ||
| Pharmacokinetics and pharmacodynamics of antimicrobials | Q36854798 | ||
| Endogenous oxidative stress produces diversity and adaptability in biofilm communities | Q36858633 | ||
| The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients | Q37033480 | ||
| Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage | Q37069059 | ||
| Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient. | Q37263761 | ||
| Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains | Q37421041 | ||
| Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. | Q37546291 | ||
| Antibiotic resistance of bacterial biofilms | Q37690946 | ||
| Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. | Q37713415 | ||
| Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy | Q37788421 | ||
| Review: Staphylococcus aureus and MRSA in cystic fibrosis | Q37896351 | ||
| Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections | Q37955633 | ||
| The intrinsic resistome of bacterial pathogens | Q38103861 | ||
| The in vivo biofilm | Q38119280 | ||
| Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors | Q38120561 | ||
| The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. | Q38130513 | ||
| Applying insights from biofilm biology to drug development - can a new approach be developed? | Q38147863 | ||
| Evolution of resistance to quorum-sensing inhibitors. | Q38160197 | ||
| DNA damage repair and bacterial pathogens | Q38163529 | ||
| PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. | Q38309969 | ||
| Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. | Q38626934 | ||
| Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations. | Q39606842 | ||
| Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis | Q39651481 | ||
| Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. | Q39653993 | ||
| Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms | Q40005043 | ||
| Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents | Q40336024 | ||
| Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms | Q40705879 | ||
| Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis | Q40834016 | ||
| SOS-independent induction of dinB transcription by beta-lactam-mediated inhibition of cell wall synthesis in Escherichia coli. | Q40943537 | ||
| Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion | Q40968218 | ||
| Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC | Q41075944 | ||
| Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation | Q41366386 | ||
| Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection | Q41741069 | ||
| Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation | Q41825397 | ||
| Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. | Q41937031 | ||
| Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections | Q41974061 | ||
| Infection prevention and control guideline for cystic fibrosis: 2013 update | Q42206103 | ||
| Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance | Q42218177 | ||
| In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens | Q42255874 | ||
| Isolation and characterization of gallium resistant Pseudomonas aeruginosa mutants. | Q42443921 | ||
| P433 | issue | 1 | |
| P921 | main subject | cystic fibrosis | Q178194 |
| antibiotic resistance | Q380775 | ||
| P304 | page(s) | 73-88 | |
| P577 | publication date | 2014-12-26 | |
| P1433 | published in | Expert Review of Respiratory Medicine | Q15754583 |
| P1476 | title | The problems of antibiotic resistance in cystic fibrosis and solutions | |
| P478 | volume | 9 |
| Q52685491 | Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. |
| Q36213685 | Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. |
| Q37428703 | Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. |
| Q89723027 | Essential oils against bacterial isolates from cystic fibrosis patients by means of antimicrobial and unsupervised machine learning approaches |
| Q57240383 | Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis |
| Q51732418 | Heterogeneous Antimicrobial Susceptibility Characteristics in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients. |
| Q90480055 | In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates |
| Q47877807 | Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis |
| Q47964862 | Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegans Pseudomonas aeruginosa Infection Model. |
| Q38623310 | Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations |
| Q40559371 | Molecular Epidemiology of Mutations in Antimicrobial Resistance Loci of Pseudomonas aeruginosa Isolates from Airways of Cystic Fibrosis Patients |
| Q64065367 | Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins |
| Q38833703 | Pseudomonas aeruginosa infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches |
| Q91655011 | Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling |
| Q91152132 | Variation of Burkholderia cenocepacia cell wall morphology and mechanical properties during cystic fibrosis lung infection, assessed by atomic force microscopy |
Search more.